We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Nov 30
BOLT Share Price Performance
US$4.89
-8.91 (-64.58%)
Price US$4.89
Share PriceUS$4.89
BOLT Community Narratives
There are no narratives available yet.
Bolt Biotherapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -26.42
- Gross Margin
- -920.33%
- Net Profit Margin
- -1,217.01%
- Debt/Equity Ratio
- 0%
Bolt Biotherapeutics, Inc. Competitors
Snowflake Analysis
About BOLT
- Founded
- 2015
- Employees
- 52
- CEO
- WebsiteView website
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.S. Market Performance
- 7 Days: -1.6%
- 3 Months: 9.8%
- 1 Year: 15.1%
- Year to Date: 8.0%
Over the last 7 days, the market has dropped 1.6%, driven by a loss of 3.6% in the Information Technology sector. In the last year, the market is actually up 15%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›